BioWorld: Rx manufacturers caught between 340B, IRA requirements
United States | In the media | January 2025
BioWorld included commentary from partner Mark Faccenda regarding IRA/340B challenges in an article discussing the uncertainties surrounding the future of 340B forms with the new administration.
Based in Washington, DC, Mark Faccenda is a member of the firm's health care practice group. He represents health care industry clients on regulatory and transactional matters.
Read the full BioWorld article, “Rx manufacturers caught between 340B, IRA requirements.”